SCHEMBL402331

SCHEMBL402331

NNc1cc[nH]c(=O)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL92516 0.77
SCHEMBL31701260 0.72 JAK2 (0.41)
SCHEMBL9199411 0.70
SCHEMBL5313969 0.69 ROCK2 (0.52)
SCHEMBL222661 0.69
SCHEMBL13373624 0.67 APEX1 (0.51)
SCHEMBL5954409 0.67 IP6K1 (0.54)
SCHEMBL6042142 0.67 NOTUM (0.77)
SCHEMBL2896727 0.67 ALDH1A1 (0.47)
SCHEMBL15901904 0.66 NPC1 (0.61)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024102639-A1 N-ARYLPYRAZOLE NOD2 AGONISTS AS PROMOTERS OF IMMUNE CHECKPOINT INHIBITOR THERAPY THE SCRIPPS RESEARCH INSTITUTE (US) 2024-05-16 WO disclosed
US-20230141198-A1 PYRAZOLOMORPHINAN DERIVATIVE THE KITASATO INSTITUTE (JP) 2023-05-11 US disclosed
US-10391175-B2 BET bromodomain inhibitors and therapeutic methods using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2019-08-27 US disclosed
US-10391175-B2 BET bromodomain inhibitors and therapeutic methods using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2019-08-27 US disclosed
US-10166236-B2 Pharmaceutical formulations comprising substituted pyrazolo[5,1-c]pyrido[4,3-e][1,2,4]triazines for treating lysosomal storage disorders PERLARA PBC (US) 2019-01-01 US disclosed
US-10053430-B2 RAF kinase modulator compounds and methods of use thereof AMBIT BIOSCIENCES CORP. (US) 2018-08-21 US disclosed
EP-2268623-B9 QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORP (US) 2018-02-28 EP disclosed
EP-2970312-B1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME UNIV MICHIGAN REGENTS (US) 2017-11-15 EP disclosed
EP-2970312-B1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME UNIV MICHIGAN REGENTS (US) 2017-11-15 EP disclosed
US-20170298029-A1 RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2017-10-19 US disclosed
US-20070004758-A1 COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE NUMERATE, INC. 2007-01-04 US disclosed
US-20070004758-A1 COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE NUMERATE, INC. 2007-01-04 US disclosed
US-20070004758-A1 COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE NUMERATE, INC. 2007-01-04 US disclosed
US-20060084695-A1 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase NUMERATE, INC. 2006-04-20 US disclosed
WO-2006028524-A2 COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE PHARMIX CORPORATION (US) 2006-03-16 WO disclosed
WO-2006025714-A1 PYRROLO[3,2-c]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2006-03-09 WO disclosed
US-20050282883-A1 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase NUMERATE, INC. 2005-12-22 US disclosed
US-20050277653-A1 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase NUMERATE, INC. 2005-12-15 US disclosed
US-20050272770-A1 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase NUMERATE, INC. 2005-12-08 US disclosed
US-20050261354-A1 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase NUMERATE, INC. 2005-11-24 US disclosed